0.2475
Theriva Biologics Inc 주식(TOVX)의 최신 뉴스
Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic - Benzinga
Benzinga
Theriva Biologics (NYSEAMERICAN:TOVX) Trading Down 4.2% - Defense World
Defense World
Theriva Biologics (NYSEAMERICAN:TOVX) Trading Down 4.2% - Defense World
Defense World
Get in on Theriva Biologics Inc's (TOVX) buy-in window today! – Sete News - SETE News
SETE News
Theriva Biologics Inc [TOVX] moved down -7.55: Why It's Important – The DBT News - The DBT News
The DBT News
Closing Figures: Theriva Biologics Inc (TOVX)'s Negative Finish at 0.31, Down -7.55 – DWinneX - The Dwinnex
The Dwinnex
Stock Surge: Theriva Biologics Inc (TOVX) Closes at 0.33, Marking a -8.56 Increase/Decrease – DWinneX - The Dwinnex
The Dwinnex
FDA grants fast track status to Theriva's cancer drug By Investing.com - Investing.com Canada
Investing.com Canada
Theriva™ Biologics anuncia la designación de vía rápida concedida por la FDA estadounidense al VCN-01 para el tratamiento del cáncer de páncreas metastásico
GlobeNewswire Inc.
Theriva gets FDA fast track status for VCN-01 for pancreatic cancer (NYSE:TOVX) - Seeking Alpha
Seeking Alpha
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of ... - GlobeNewswire
GlobeNewswire
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of ... - Yahoo Finance
Yahoo Finance
Sidoti's December Small-Cap Virtual Conference - The Globe and Mail
The Globe and Mail
Another Biotech Stealing The Premarket Spotlight - The Globe and Mail
The Globe and Mail
Theriva™ Biologics to Participate in the A.G.P. Virtual - GlobeNewswire
GlobeNewswire
Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference - Yahoo Finance
Yahoo Finance
Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference - Yahoo Finance
Yahoo Finance
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2024
GlobeNewswire Inc.
Theriva Biologics: Q1 Earnings Snapshot - Houston Chronicle
Houston Chronicle
Theriva Biologics Faces Liquidity Crisis: Urgent Capital Needed to Sustain Operations and Clinical Programs ... - TipRanks
TipRanks
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - GlobeNewswire
GlobeNewswire
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - Yahoo Finance
Yahoo Finance
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - Yahoo Finance
Yahoo Finance
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered ... - Yahoo Finance
Yahoo Finance
Theriva Biologics' VCN-01 Shows Promise in Pediatric Cancer Trial - TipRanks.com - TipRanks
TipRanks
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Abeona Therapeutics ( - Benzinga
Benzinga
Theriva Biologics Reports Breakthrough in Pancreatic Cancer Therapy - TipRanks.com - TipRanks
TipRanks
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
GlobeNewswire Inc.
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic ... - Yahoo Finance
Yahoo Finance
Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Diff - Benzinga
Benzinga
Theriva™ Biologics anuncia su presentación en la 27ª Reunión Anual de la Sociedad Americana de Terapia Celular y Génica
GlobeNewswire Inc.
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting - Yahoo Finance
Yahoo Finance
Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript March 25, 2024 - Yahoo Finance
Yahoo Finance
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
GlobeNewswire Inc.
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results - Yahoo Finance
Yahoo Finance
Theriva™ Biologics realizará una teleconferencia y retransmisión por Internet para comentar los aspectos operativos más destacados y los resultados financieros del ejercicio 2023
GlobeNewswire Inc.
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
GlobeNewswire Inc.
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and ... - Yahoo Finance
Yahoo Finance
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
GlobeNewswire Inc.
Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could - Benzinga
Benzinga
Simtra BioPharma to invest $250m in US facility - Pharmaceutical Technology
Pharmaceutical Technology
Theriva Biologics Reports Positive Phase 2b Trial Progress - TipRanks.com - TipRanks
TipRanks
Theriva Biologics anuncia la recomendación positiva del Comité independiente para la monitorización de los datos de Datos de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico
GlobeNewswire Inc.
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE ... - Yahoo Finance
Yahoo Finance
Theriva Biologics participará en la Conferencia Anual de Oncología de B. Riley Securities
GlobeNewswire Inc.
US dosing begins in Theriva's VIRAGE pancreatic cancer trial - Clinical Trials Arena
Clinical Trials Arena
Why Is AST SpaceMobile (ASTS) Stock Down 28% Today? - InvestorPlace
InvestorPlace
Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of ... - Yahoo Finance
Yahoo Finance
Theriva Biologics Appoints Ramon Alemany, Ph.D., as Senior Vice President of Discovery - citybiz
citybiz
자본화:
|
볼륨(24시간):